TY - JOUR A1 - Barcelo-Coblijn, Gwendolyn A1 - Laura Martin, Maria A1 - de Almeida, Rodrigo F. M. A1 - Antonia Noguera-Salva, Maria A1 - Marcilla-Etxenike, Amaia A1 - Guardiola-Serrano, Francisca A1 - Lueth, Anja A1 - Kleuser, Burkhard A1 - Halver, John E. A1 - Escriba, Pablo V. T1 - Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy JF - Proceedings of the National Academy of Sciences of the United States of America N2 - The mechanism of action of 2-hydroxyoleic acid (2OHOA), a potent antitumor compound, has not yet been fully elucidated. Here, we show that human cancer cells have markedly lower levels of sphingomyelin (SM) than nontumor (MRC-5) cells. In this context, 2OHOA treatment strongly augments SM mass (4.6-fold), restoring the levels found in MRC-5 cells, while a loss of phosphatidylethanolamine and phosphatidylcholine is observed (57 and 30%, respectively). The increased SM mass was due to a rapid and highly specific activation of SM synthases (SMS). This effect appeared to be specific against cancer cells as it did not affect nontumor MRC-5 cells. Therefore, low SM levels are associated with the tumorigenic transformation that produces cancer cells. SM accumulation occurred at the plasma membrane and caused an increase in membrane global order and lipid raft packing in model membranes. These modifications would account for the observed alteration by 2OHOA in the localization of proteins involved in cell apoptosis (Fas receptor) or differentiation (Ras). Importantly, SMS inhibition by D609 diminished 2OHOA effect on cell cycle. Therefore, we propose that the regulation of SMS activity in tumor cells is a critical upstream event in 2OHOA antitumor mechanism, which also explains its specificity for cancer cells, its potency, and the lack of undesired side effects. Finally, the specific activation of SMS explains the ability of this compound to trigger cell cycle arrest, cell differentiation, and autophagy or apoptosis in cancer cells. KW - anticancer KW - membrane-lipid therapy KW - lung cancer KW - membrane lipids Y1 - 2011 U6 - https://doi.org/10.1073/pnas.1115484108 SN - 0027-8424 VL - 108 IS - 49 SP - 19569 EP - 19574 PB - National Acad. of Sciences CY - Washington ER - TY - GEN A1 - Bäumer, Wolfgang A1 - Rossbach, Kristine A1 - Mischke, Reinhard A1 - Reines, Ilka A1 - Langbein-Detsch, Ines A1 - Lüth, Anja A1 - Kleuser, Burkhard T1 - Decreased concentration and enhanced metabolism of sphingosine-1-Phosphate in lesional skin of dogs with atopic dermatitis disturbed Sphingosine-1-Phosphate homeostasis in atopic Dermatitis T2 - The journal of investigative dermatology Y1 - 2011 U6 - https://doi.org/10.1038/jid.2010.252 SN - 0022-202X VL - 131 IS - 1 SP - 266 EP - 268 PB - Nature Publ. Group CY - New York ER - TY - JOUR A1 - Lüth, Anja A1 - Neuber, Corinna A1 - Kleuser, Burkhard T1 - Novel methods for the quantification of (2E)-hexadecenal by liquid chromatography with detection by either ESI QTOF tandem mass spectrometry or fluorescence measurement JF - Analytica chimica acta : an international journal devoted to all branches of analytical chemistry N2 - Sphingosine-1-phosphate lyase (SPL) is the only known enzyme that irreversibly cleaves sphingosine-1-phosphate (S1P) into phosphoethanolamine and (2E)-hexadecenal during the final step of sphingolipid catabolism. Because S1P is involved in a wide range of physiological and diseased processes, determining the activity of the degrading enzyme is of great interest. Therefore, we developed two procedures based on liquid chromatography (LC) for analysing (2E)-hexadecenal, which is one of the two S1P degradation products. After separation, two different quantification methods were performed, tandem mass spectrometry (MS) and fluorescence detection. However, (2E)-hexadecenal as a long-chain aldehyde is not ionisable by electrospray ionisation (ESI) for MS quantification and has an insufficient number of corresponding double bonds for fluorescence detection. Therefore, we investigated 2-diphenylacetyl-1,3-indandione-1-hydrazone (DAIH) as a derivatisation reagent. DAIH transforms the aldehyde into an ionisable and fluorescent analogue for quantitative analysis. Our conditions were optimised to obtain the outstanding limit of detection (LOD) of 1 fmol per sample (30 mu L) for LC-MS/MS and 0.75 pmol per sample (200 mu l) for LC determination with fluorescence detection. We developed an extraction procedure to separate and concentrate (2E)-hexadecenal from biological samples for these measurements. To confirm our new methods, we analysed the (2E)-hexadecenal level of different cell lines and human plasma for the first time ever. Furthermore, we treated HT-29 cells with different concentrations of 4-deoxypyridoxine (DOP), which competitively inhibits pyridoxal-5-phosphate (P5P), an essential cofactor for SPL activity, and observed a significant decrease in (2E)-hexadecenal relative to the untreated cells. KW - (2E)-Hexadecenal KW - Sphingosine-1-phosphate lyase KW - Derivatisation KW - Tandem mass spectrometry KW - Fluorescence Y1 - 2012 U6 - https://doi.org/10.1016/j.aca.2012.01.063 SN - 0003-2670 VL - 722 SP - 70 EP - 79 PB - Elsevier CY - Amsterdam ER - TY - CHAP A1 - Boehm, Andreas A1 - Polzin, A. A1 - Lueth, Anja A1 - Kleuser, Burkhard A1 - Rassaf, T. A1 - Kelm, M. A1 - Kroemer, H. K. A1 - Schroer, K. A1 - Rauch, B. H. T1 - The release of sphingosine-1-phosphate from human platelets during acute coronary syndrome is attenuated by aspirin T2 - NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY Y1 - 2012 SN - 0028-1298 VL - 385 SP - 12 EP - 12 PB - Springer CY - New York ER - TY - CHAP A1 - Schaper, K. A1 - Kietzmann, M. A1 - Kleuser, Burkhard A1 - Baeumer, W. T1 - Effects of sphingosine-1-phosphate and FTY720 on epidermal hyperproliferation and inflammation in an imiquimod induced mouse model of psoriasis T2 - NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY Y1 - 2012 SN - 0028-1298 VL - 385 IS - 3 SP - 80 EP - 80 PB - Springer CY - New York ER - TY - JOUR A1 - Schmitz, Elisabeth I. A1 - Potteck, Henrik A1 - Schüppel, Melanie A1 - Manggau, Marianti A1 - Wahydin, Elly A1 - Kleuser, Burkhard T1 - Sphingosine 1-phosphate protects primary human keratinocytes from apoptosis via nitric oxide formation through the receptor subtype S1P(3) JF - Molecular and cellular biochemistry : an international journal for chemical biology in health and disease N2 - Although the lipid mediator sphingosine 1-phosphate (S1P) has been identified to induce cell growth arrest of human keratinocytes, the sphingolipid effectively protects these epidermal cells from apoptosis. The molecular mechanism of the anti-apoptotic action induced by S1P is less characterized. Apart from S1P, endogenously produced nitric oxide (NOaEuro cent) has been recognized as a potent modulator of apoptosis in keratinocytes. Therefore, it was of great interest to elucidate whether S1P protects human keratinocytes via a NOaEuro cent-dependent signalling pathway. Indeed, S1P induced an activation of endothelial nitric oxide synthase (eNOS) in human keratinocytes leading to an enhanced formation of NOaEuro cent. Most interestingly, the cell protective effect of S1P was almost completely abolished in the presence of the eNOS inhibitor L-NAME as well as in eNOS-deficient keratinocytes indicating that the sphingolipid metabolite S1P protects human keratinocytes from apoptosis via eNOS activation and subsequent production of protective amounts of NOaEuro cent. It is well established that most of the known actions of S1P are mediated by a family of five specific G protein-coupled receptors. Therefore, the involvement of S1P-receptor subtypes in S1P-mediated eNOS activation has been examined. Indeed, this study clearly shows that the S1P(3) is the exclusive receptor subtype in human keratinocytes which mediates eNOS activation and NOaEuro cent formation in response to S1P. In congruence, when the S1P(3) receptor subtype is abrogated, S1P almost completely lost its ability to protect human keratinocytes from apoptosis. KW - Keratinocytes KW - Sphingolipids KW - Sphingosine 1-phosphate KW - S1P-receptors KW - Nitric oxide KW - Endothelial nitric oxide synthase KW - Apoptosis Y1 - 2012 U6 - https://doi.org/10.1007/s11010-012-1433-5 SN - 0300-8177 VL - 371 IS - 1-2 SP - 165 EP - 176 PB - Springer CY - Dordrecht ER - TY - CHAP A1 - Natek, M. A1 - Lüth, Anja A1 - Kleuser, Burkhard A1 - Schäfer-Korting, M. A1 - Weindl, G. T1 - CpG-oligonucleotides modulate sphingosine-1-phosphate metabolism in normal human keratinocytes T2 - The journal of investigative dermatology Y1 - 2012 SN - 0022-202X VL - 132 IS - 5 SP - S112 EP - S112 PB - Nature Publ. Group CY - New York ER - TY - JOUR A1 - Japtok, Lukasz A1 - Schaper, Katrin A1 - Bäumer, Wolfgang A1 - Radeke, Heinfried H. A1 - Jeong, Se Kyoo A1 - Kleuser, Burkhard T1 - Sphingosine 1-Phosphate Modulates Antigen Capture by Murine Langerhans Cells via the S1P(2) Receptor Subtype JF - PLOS ONE N2 - Dendritic cells (DCs) play a pivotal role in the development of cutaneous contact hypersensitivity (CHS) and atopic dermatitis as they capture and process antigen and present it to T lymphocytes in the lymphoid organs. Recently, it has been indicated that a topical application of the sphingolipid sphingosine 1-phosphate (S1P) prevents the inflammatory response in CHS, but the molecular mechanism is not fully elucidated. Here we indicate that treatment of mice with S1P is connected with an impaired antigen uptake by Langerhans cells (LCs), the initial step of CHS. Most of the known actions of S1P are mediated by a family of five specific G protein-coupled receptors. Our results indicate that S1P inhibits macropinocytosis of the murine LC line XS52 via S1P(2) receptor stimulation followed by a reduced phosphatidylinositol 3-kinase (PI3K) activity. As down-regulation of S1P(2) not only diminished S1P-mediated action but also enhanced the basal activity of LCs on antigen capture, an autocrine action of S1P has been assumed. Actually, S1P is continuously produced by LCs and secreted via the ATP binding cassette transporter ABCC1 to the extracellular environment. Consequently, inhibition of ABCC1, which decreased extracellular S1P levels, markedly increased the antigen uptake by LCs. Moreover, stimulation of sphingosine kinase activity, the crucial enzyme for S1P formation, is connected not only with enhanced S1P levels but also with diminished antigen capture. These results indicate that S1P is essential in LC homeostasis and influences skin immunity. This is of importance as previous reports suggested an alteration of S1P levels in atopic skin lesions. Citation: Japtok L, Schaper K, Baumer W, Radeke HH, Jeong SK, et al. (2012) Sphingosine 1-Phosphate Modulates Antigen Capture by Murine Langerhans Cells via the S1P(2) Receptor Subtype. PLoS ONE 7(11): e49427. doi:10.1371/journal.pone.0049427 Y1 - 2012 U6 - https://doi.org/10.1371/journal.pone.0049427 SN - 1932-6203 VL - 7 IS - 11 PB - PUBLIC LIBRARY SCIENCE CY - SAN FRANCISCO ER - TY - JOUR A1 - Gerecke, Christian A1 - Mascher, Conny A1 - Gottschalk, Uwe A1 - Kleuser, Burkhard A1 - Scholtka, Bettina T1 - Ultrasensitive detection of unknown colon cancer-initiating mutations using the example of the adenomatous polyposis coli gene JF - Cancer prevention research N2 - Detection of cancer precursors contributes to cancer prevention, for example, in the case of colorectal cancer. To record more patients early, ultrasensitive methods are required for the purpose of noninvasive precursor detection in body fluids. Our aim was to develop a method for enrichment and detection of known as well as unknown driver mutations in the Adenomatous polyposis coli (APC) gene. By coupled wild-type blocking (WTB) PCR and high-resolution melting (HRM), referred to as WTB-HRM, a minimum detection limit of 0.01% mutant in excess wild-type was achieved according to as little as 1 pg mutated DNA in the assay. The technique was applied to 80 tissue samples from patients with colorectal cancer (n = 17), adenomas (n = 50), serrated lesions (n = 8), and normal mucosa (n = 5). Any kind of known and unknown APC mutations (deletions, insertions, and base exchanges) being situated inside the mutation cluster region was distinguishable from wild-type DNA. Furthermore, by WTB-HRM, nearly twice as many carcinomas and 1.5 times more precursor lesions were identified to be mutated in APC, as compared with direct sequencing. By analyzing 31 associated stool DNA specimens all but one of the APC mutations could be recovered. Transferability of the WTB-HRM method to other genes was proven using the example of KRAS mutation analysis. In summary, WTB-HRM is a new approach for ultrasensitive detection of cancer-initiating mutations. In this sense, it appears especially applicable for noninvasive detection of colon cancer precursors in body fluids with excess wild-type DNA like stool. Cancer Prev Res; 6(9); 898-907. (C) 2013 AACR. Y1 - 2013 U6 - https://doi.org/10.1158/1940-6207.CAPR-13-0145 SN - 1940-6207 VL - 6 IS - 9 SP - 898 EP - 907 PB - American Association for Cancer Research CY - Philadelphia ER - TY - JOUR A1 - Lotinun, Sutada A1 - Kiviranta, Riku A1 - Matsubara, Takuma A1 - Alzate, Jorge A. A1 - Neff, Lynn A1 - Lüth, Anja A1 - Koskivirta, Ilpo A1 - Kleuser, Burkhard A1 - Vacher, Jean A1 - Vuorio, Eero A1 - Horne, William C. A1 - Baron, Roland T1 - Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation JF - The journal of clinical investigation N2 - Cathepsin K (CTSK) is secreted by osteoclasts to degrade collagen and other matrix proteins during bone resorption. Global deletion of Ctsk in mice decreases bone resorption, leading to osteopetrosis, but also increases the bone formation rate (BFR). To understand how Ctsk deletion increases the BFR, we generated osteoclast- and osteoblast-targeted Ctsk knockout mice using floxed Ctsk alleles. Targeted ablation of Ctsk in hematopoietic cells, or specifically in osteoclasts and cells of the monocyte-osteoclast lineage, resulted in increased bone volume and BFR as well as osteoclast and osteoblast numbers. In contrast, targeted deletion of Ctsk in osteoblasts had no effect on bone resorption or BFR, demonstrating that the increased BFR is osteoclast dependent. Deletion of Ctsk in osteoclasts increased their sphingosine kinase 1 (Sphk1) expression. Conditioned media from Ctsk-deficient osteoclasts, which contained elevated levels of sphingosine-l-phosphate (S1P), increased alkaline phosphatase and mineralized nodules in osteoblast cultures. An S1P(1,3) receptor antagonist inhibited these responses. Osteoblasts derived from mice with Ctsk-deficient osteoclasts had an increased RANKL/OPG ratio, providing a positive feedback loop that increased the number of osteoclasts. Our data provide genetic evidence that deletion of CTSK in osteoclasts enhances bone formation in vivo by increasing the generation of osteoclast-derived S1P. Y1 - 2013 U6 - https://doi.org/10.1172/JCI64840 SN - 0021-9738 VL - 123 IS - 2 SP - 666 EP - 681 PB - American Society for Clinical Investigation CY - Ann Arbor ER - TY - JOUR A1 - Bhabak, Krishna P. A1 - Kleuser, Burkhard A1 - Huwiler, Andrea A1 - Arenz, Christoph T1 - Effective inhibition of acid and neutral ceramidases by novel B-13 and LCL-464 analogues JF - Bioorganic & medicinal chemistry : a Tetrahedron publication for the rapid dissemination of full original research papers and critical reviews on biomolecular chemistry, medicinal chemistry and related disciplines N2 - Induction of apoptosis mediated by the inhibition of ceramidases has been shown to enhance the efficacy of conventional chemotherapy in several cancer models. Among the inhibitors of ceramidases reported in the literature, B-13 is considered as a lead compound having good in vitro potency towards acid ceramidase. Furthermore, owing to the poor activity of B-13 on lysosoamal acid ceramidase in living cells, LCL-464 a modified derivative of B-13 containing a basic omega-amino group at the fatty acid was reported to have higher potency towards lysosomal acid ceramidase in living cells. In a search for more potent inhibitors of ceramidases, we have designed a series of compounds with structural modifications of B-13 and LCL-464. In this study, we show that the efficacy of B-13 in vitro as well as in intact cells can be enhanced by suitable modification of functional groups. Furthermore, a detailed SAR investigation on LCL-464 analogues revealed novel promising inhibitors of aCDase and nCDase. In cell culture studies using the breast cancer cell line MDA-MB-231, some of the newly developed compounds elevated endogenous ceramide levels and in parallel, also induced apoptotic cell death. In summary, this study shows that structural modification of the known ceramidase inhibitors B-13 and LCL-464 generates more potent ceramidase inhibitors that are active in intact cells and not only elevates the cellular ceramide levels, but also enhances cell death. KW - Sphingolipids KW - Ceramide KW - Ceramidase inhibitors KW - Structure-activity-relationship Y1 - 2013 U6 - https://doi.org/10.1016/j.bmc.2012.12.014 SN - 0968-0896 VL - 21 IS - 4 SP - 874 EP - 882 PB - Elsevier CY - Oxford ER - TY - GEN A1 - Polzin, Amin A1 - Rassaf, Tienush A1 - Boehm, Andreas A1 - Lueth, Anja A1 - Kleuser, Burkhard A1 - Zeus, Tobias A1 - Kelm, Malte A1 - Kroemer, Heyo K. A1 - Schroer, Karsten A1 - Rauch, Bernhard H. T1 - Aspirin inhibits release of platelet-derived sphingosine-1-phosphate in acute myocardial infarction T2 - INTERNATIONAL JOURNAL OF CARDIOLOGY KW - Sphingosine-1-phosphate KW - Acute coronary syndrome KW - Platelets KW - Aspirin Y1 - 2013 U6 - https://doi.org/10.1016/j.ijcard.2013.10.050 SN - 0167-5273 SN - 1874-1754 VL - 170 IS - 2 SP - E23 EP - E24 PB - ELSEVIER IRELAND LTD CY - CLARE ER - TY - JOUR A1 - Gulbins, Erich A1 - Palmada, Monica A1 - Reichel, Martin A1 - Lueth, Anja A1 - Boehmer, Christoph A1 - Amato, Davide A1 - Mueller, Christian P. A1 - Tischbirek, Carsten H. A1 - Groemer, Teja W. A1 - Tabatabai, Ghazaleh A1 - Becker, Katrin Anne A1 - Tripal, Philipp A1 - Staedtler, Sven A1 - Ackermann, Teresa F. A1 - van Brederode, Johannes A1 - Alzheimer, Christian A1 - Weller, Michael A1 - Lang, Undine E. A1 - Kleuser, Burkhard A1 - Grassme, Heike A1 - Kornhuber, Johannes T1 - Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs JF - Nature medicine N2 - Major depression is a highly prevalent severe mood disorder that is treated with antidepressants. The molecular targets of antidepressants require definition. We investigated the role of the acid sphingomyelinase (Asm)-ceramide system as a target for antidepressants. Therapeutic concentrations of the antidepressants amitriptyline and fluoxetine reduced Asm activity and ceramide concentrations in the hippocampus, increased neuronal proliferation, maturation and survival and improved behavior in mouse models of stress-induced depression. Genetic Asm deficiency abrogated these effects. Mice overexpressing Asm, heterozygous for acid ceramidase, treated with blockers of ceramide metabolism or directly injected with C16 ceramide in the hippocampus had higher ceramide concentrations and lower rates of neuronal proliferation, maturation and survival compared with controls and showed depression-like behavior even in the absence of stress. The decrease of ceramide abundance achieved by antidepressant-mediated inhibition of Asm normalized these effects. Lowering ceramide abundance may thus be a central goal for the future development of antidepressants. Y1 - 2013 U6 - https://doi.org/10.1038/nm.3214 SN - 1078-8956 VL - 19 IS - 7 SP - 934 EP - + PB - Nature Publ. Group CY - New York ER - TY - JOUR A1 - Böhm, Andreas A1 - Flößer, Anja A1 - Ermler, Swen A1 - Fender, Anke C. A1 - Lüth, Anja A1 - Kleuser, Burkhard A1 - Schrör, Karsten A1 - Rauch, Bernhard H. T1 - Factor-Xa-induced mitogenesis and migration require sphingosine kinase activity and S1P formation in human vascular smooth muscle cells JF - Cardiovascular research N2 - Sphingosine-1-phosphate (S1P) is a cellular signalling lipid generated by sphingosine kinase-1 (SPHK1). The aim of the study was to investigate whether the activated coagulation factor-X (FXa) regulates SPHK1 transcription and the formation of S1P and subsequent mitogenesis and migration of human vascular smooth muscle cells (SMC). FXa induced a time- (36 h) and concentration-dependent (330 nmol/L) increase of SPHK1 mRNA and protein expression in human aortic SMC, resulting in an increased synthesis of S1P. FXa-stimulated transcription of SPHK1 was mediated by the protease-activated receptor-1 (PAR-1) and PAR-2. In human carotid artery plaques, expression of SPHK1 was observed at SMC-rich sites and was co-localized with intraplaque FX/FXa content. FXa-induced SPHK1 transcription was attenuated by inhibitors of Rho kinase (Y27632) and by protein kinase C (PKC) isoforms (GF109203X). In addition, FXa rapidly induced the activation of the small GTPase Rho A. Inhibition of signalling pathways which regulate SPHK1 expression, inhibition of its activity or siRNA-mediated SPHK1 knockdown attenuated the mitogenic and chemotactic response of human SMC to FXa. These data suggest that FXa induces SPHK1 expression and increases S1P formation independent of thrombin and that this involves the activation of Rho A and PKC signalling. In addition to its key function in coagulation, this direct effect of FXa on human SMC may increase cell proliferation and migration at sites of vessel injury and thereby contribute to the progression of vascular lesions. KW - Factor-Xa KW - Atherosclerosis KW - Proliferation KW - Smooth muscle cells KW - Sphingosine kinase-1 Y1 - 2013 U6 - https://doi.org/10.1093/cvr/cvt112 SN - 0008-6363 VL - 99 IS - 3 SP - 505 EP - 513 PB - Oxford Univ. Press CY - Oxford ER - TY - JOUR A1 - Schaper, Katrin A1 - Dickhaut, Jeannette A1 - Japtok, Lukasz A1 - Kietzmann, Manfred A1 - Mischke, Reinhard A1 - Kleuser, Burkhard A1 - Bäumer, Wolfgang T1 - Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis JF - Journal of dermatological scienc N2 - Background: It has been indicated that the sphingolipid sphingosine-1-phosphate (SIP) restrains the ability of dendritic cells to migrate to lymph nodes. Furthermore SIP has been demonstrated to inhibit cell growth in human keratinocytes. However, only little is known about the effect of S1P in hyperproliferative and inflammatory in vivo models. Objective: In this study, locally acting SIP was explored in different experimental mouse models of psoriasis vulgaris. Methods: S1P and FTY720 were tested in the imiquimod-induced psoriasis mouse model, the mouse tail assay and a pilot study of the severe combined immunodeficiency mice (SCID). Results: In the imiquimod model the positive control diflorasone diacetate and S1P, but not FTY720 reduced the imiquimod-induced epidermal hyperproliferation of the ear skin. This effect was confirmed in the SCID model, where S1P treated skin from patients suffering from psoriasis showed a decrease in epidermal thickness compared to vehicle. In the imiquimod model, there was also significant inhibition of ear swelling and a moderate reduction of inflammatory cell influx and oedema formation in ear skin by SIP treatment. The inflammatory response on the back skin was, however, only reduced by diflorasone diacetate. In the mouse tail assay, the influence of S1P and FTY720 in stratum granulosum formation was tested compared to the positive control calcipotriol. Whereas topical administration of calcipotriol led to a low but significant increase of stratum granulosum, S1P and FTY720 lacked such an effect. Conclusion: Taken together, these results imply that topical administration of SIP might be a new option for the treatment of mild to moderate psoriasis lesions. KW - Imiquimod KW - Psoriasis KW - SCID mice KW - Sphingosine-1-phosphate Y1 - 2013 U6 - https://doi.org/10.1016/j.jdermsci.2013.03.006 SN - 0923-1811 VL - 71 IS - 1 SP - 29 EP - 36 PB - Elsevier CY - Clare ER - TY - JOUR A1 - Putra, Sulistyo Emantoko Dwi A1 - Neuber, Corinna A1 - Reichetzeder, Christoph A1 - Hocher, Berthold A1 - Kleuser, Burkhard T1 - Analysis of genomic DNA methylation levels in human placenta using liquid Chromatography-Electrospray ionization tandem mass spectrometry JF - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry and pharmacology N2 - Background: DNA-methylation is a common epigenetic tool which plays a crucial role in gene regulation and is essential for cell differentiation and embryonic development. The placenta is an important organ where gene activity can be regulated by epigenetic DNA modifications, including DNA methylation. This is of interest as, the placenta is the interface between the fetus and its environment, the mother. Exposure to environmental toxins and nutrition during pregnancy may alter DNA methylation of the placenta and subsequently placental function and as a result the phenotype of the offspring. The aim of this study was to develop a reliable method to quantify DNA methylation in large clinical studies. This will be a tool to analyze the degree of DNA methylation in the human placenta in relationship to clinical readouts. Methods: Liquid chromatography-electrospray ionization/multi-stage mass spectrometry (LC-ESI/MS/MS) technique was used for the quantification of the 5dmC/dG ratio in placentas from 248 healthy pregnancies. We were able to demonstrate that this method is a reliable and stable way to determine global placental DNA methylation in large clinical trials. Results/Conclusion: The degree of placental DNA methylation seen in our pilot study varies substantially from 2% to 5%. The clinical implications of this variation need to be demonstrated in adequately powered large studies. KW - Pregnancy KW - Placenta KW - Methylation KW - Global KW - LC-MS/MS KW - Fetal programming KW - Clinical Y1 - 2014 U6 - https://doi.org/10.1159/000358666 SN - 1015-8987 SN - 1421-9778 VL - 33 IS - 4 SP - 945 EP - 952 PB - Karger CY - Basel ER - TY - CHAP A1 - Arlt, Olga A1 - Schwiebs, Anja A1 - Pfarr, Kathrin A1 - Ranglack, Annika A1 - Bouzas, Ferreiros Nerea A1 - Schreiber, Yannick A1 - Neuber, Corinna A1 - Kleuser, Burkhard A1 - Pfeilschifter, Josef M. A1 - Radeke, Heinfried H. T1 - Dynamic interaction between sphingolipid enzymes, S1P and inflammatory cytokine regulation in dendritic cells T2 - NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY Y1 - 2014 SN - 0028-1298 SN - 1432-1912 VL - 387 SP - S91 EP - S91 PB - Springer CY - New York ER - TY - JOUR A1 - Imeri, Faik A1 - Fallegger, Daniel A1 - Zivkovic, Aleksandra A1 - Schwalm, Stephanie A1 - Enzmann, Gaby A1 - Blankenbach, Kira A1 - Heringdorf, Dagmar Meyer Zu A1 - Homann, Thomas A1 - Kleuser, Burkhard A1 - Pfeilschifter, Josef A1 - Engelhardt, Britta A1 - Stark, Holger A1 - Huwiler, Andrea T1 - Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice JF - Neuropharmacology N2 - The immunomodulatory FTY720 (fingolimod) is presently approved for the treatment of relapsing-remitting multiple sclerosis. It is a prodrug that acts by modulating sphingosine 1-phosphate (S1P) receptor signaling. In this study, we have developed and characterized two novel oxazolo-oxazole derivatives of FTY720, ST-968 and the oxy analog ST-1071, which require no preceding activating phosphorylation, and proved to be active in intact cells and triggered S1P(1) and S1P(3), but not S1P(2), receptor internalization as a result of receptor activation. Functionally, ST-968 and ST-1071 acted similar to FTY720 to abrogate S1P-triggered chemotaxis of mouse splenocytes, mouse T cells and human U937 cells, and reduced TNFa- and LPS-stimulated endothelial cell permeability. The compounds also reduced TNF alpha-induced ICAM-1 and VCAM-1 mRNA expression, but restored TNF alpha-mediated downregulation of PECAM-1 mRNA expression. In an in vivo setting, the application of ST-968 or ST-1071 to mice resulted in a reduction of blood lymphocytes and significantly reduced the clinical symptoms of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice comparable to FTY720 either by prophylactic or therapeutic treatment. In parallel to the reduced clinical symptoms, infiltration of immune cells in the brain was strongly reduced, and in isolated tissues of brain and spinal cord, the mRNA and protein expressions of ICAM-1 and VCAM-1, as well as of matrix metalloproteinase-9 were reduced by all compounds, whereas PECAM-1 and tissue inhibitor of metalloproteinase TIMP-1 were upregulated. In summary, the data suggest that these novel butterfly derivatives of FTY720 could have considerable implication for future therapies of multiple sclerosis and other autoimmune diseases. (C) 2014 Elsevier Ltd. All rights reserved. KW - Fingolimod KW - ST-968 KW - ST-1071 KW - Sphingosine 1-phosphate KW - Endothelial cells KW - Permeability KW - Multiple sclerosis Y1 - 2014 U6 - https://doi.org/10.1016/j.neuropharm.2014.05.012 SN - 0028-3908 SN - 1873-7064 VL - 85 SP - 314 EP - 327 PB - Elsevier CY - Oxford ER - TY - JOUR A1 - Keller, Johannes A1 - Catala-Lehnen, Philip A1 - Huebner, Antje K. A1 - Jeschke, Anke A1 - Heckt, Timo A1 - Lueth, Anja A1 - Krause, Matthias A1 - Koehne, Till A1 - Albers, Joachim A1 - Schulze, Jochen A1 - Schilling, Sarah A1 - Haberland, Michael A1 - Denninger, Hannah A1 - Neven, Mona A1 - Hermans-Borgmeyer, Irm A1 - Streichert, Thomas A1 - Breer, Stefan A1 - Barvencik, Florian A1 - Levkau, Bodo A1 - Rathkolb, Birgit A1 - Wolf, Eckhard A1 - Calzada-Wack, Julia A1 - Neff, Frauke A1 - Gailus-Durner, Valerie A1 - Fuchs, Helmut A1 - de Angelis, Martin Hrabe A1 - Klutmann, Susanne A1 - Tsourdi, Elena A1 - Hofbauer, Lorenz C. A1 - Kleuser, Burkhard A1 - Chun, Jerold A1 - Schinke, Thorsten A1 - Amling, Michael T1 - Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts JF - Nature Communications N2 - The hormone calcitonin (CT) is primarily known for its pharmacologic action as an inhibitor of bone resorption, yet CT-deficient mice display increased bone formation. These findings raised the question about the underlying cellular and molecular mechanism of CT action. Here we show that either ubiquitous or osteoclast-specific inactivation of the murine CT receptor (CTR) causes increased bone formation. CT negatively regulates the osteoclast expression of Spns2 gene, which encodes a transporter for the signalling lipid sphingosine 1-phosphate (S1P). CTR-deficient mice show increased S1P levels, and their skeletal phenotype is normalized by deletion of the S1P receptor S1P(3). Finally, pharmacologic treatment with the nonselective S1P receptor agonist FTY720 causes increased bone formation in wild-type, but not in S1P(3)-deficient mice. This study redefines the role of CT in skeletal biology, confirms that S1P acts as an osteoanabolic molecule in vivo and provides evidence for a pharmacologically exploitable crosstalk between osteoclasts and osteoblasts. Y1 - 2014 U6 - https://doi.org/10.1038/ncomms6215 SN - 2041-1723 VL - 5 PB - Nature Publ. Group CY - London ER - TY - CHAP A1 - Baranyai, Dorothea A1 - Goedtel-Armbrust, Ute A1 - Nestler, Sebastian A1 - Kleuser, Burkhard A1 - Wojnowski, Leszek T1 - A role for cutaneous CYP3A in vitamin D homeostasis? T2 - NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY Y1 - 2014 SN - 0028-1298 SN - 1432-1912 VL - 387 SP - S27 EP - S27 PB - Springer CY - New York ER -